Business Wire·Aug 13, 2026, 9:07 AM ET

bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. entered a securities purchase agreement to sell 8,462,027 shares of common stock or pre-funded warrants along with two warrants to purchase up to 16,924,054 shares in a private placement.
The offering is priced at-the-market under Nasdaq rules with a combined effective price of $0.4727 per share/warrant unit, while the pre-funded warrant component alone has a price of $0.4657.
Pre-funded warrants carry an exercise price of $0.007 per share, whereas the accompanying warrants have an exercise price of $0.4727 per share and will be exercisable after stockholder approval.
All warrants issued in this transaction will expire five years from the date of issuance.
The offering is estimated to generate approximately $4.0 million in gross proceeds before deducting placement agent fees and other expenses.
WallachBeth Capital LLC is acting as the sole placement agent for the transaction.
The offering is expected to close on or about August 14, 2026, subject to customary closing conditions.
The securities were sold under Section 4(a)(2) of the Securities Act and/or Regulation D, meaning they are unregistered and cannot be resold in the U.S. without an effective registration statement or applicable exemption.
bioAffinity Technologies focuses on noninvasive diagnostics for early-stage cancer, with its primary product CyPath® Lung marketed as a Laboratory Developed Test by Precision Pathology Laboratory Services.